Kwangdong Pharmaceutical Signs Exclusive License Agreement For OCU400 Korea For Candidates For Ocugen Retinal Pigment Degeneration Gene Therapy
Sep 17, 2025
|
OCU400 is currently being evaluated in the global phase 3 clinical trial, and Ocugen is aiming to apply for FDA clearance in 2026. Kwangdong Pharmaceutical plans to proceed with the domestic licensing process based on global clinical results and licensing data.
Retinal pigment degeneration is a rare disease that can gradually damage the retina due to genetic factors, narrowing the field of vision and eventually leading to blindness, and the number of patients in Korea is estimated to be about 7,000.
Through this contract, Kwangdong Pharmaceutical will strengthen its portfolio in the ophthalmology sector along with existing presbyopia and pediatric nearsighted pipelines. Kwangdong Pharmaceutical has secured various pipelines such as Brimochol, a candidate for presbyopia treatment, NVK002, a new drug candidate for pediatric nearsightedness, and Raxone, a treatment for rare ophthalmic diseases, and is fostering the ophthalmic field as a next-generation growth engine.
"It is very meaningful to be able to convey new hope to patients with retinal pigment degeneration in Korea. We will do our best to provide treatment as soon as the clinical trial is completed," said an official from Kwangdong Pharmaceutical."
This article was translated by Naver AI translator.
